Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.
Jessen F, Arbizu J, Boada M, Balasa M, Bennys K, Boban M, Bürger K, Chincarini A, Cagnin A, De Deyn PP, Düzel E, Engelborghs S, Ewers M, Exalto LG, van der Flier WM, Fortea J, Frederiksen KS, Frisoni GB, Frölich L, Garza-Martinez AJ, Grimmer T, Hanseeuw B, Hort J, Ivanoiu A, Kehoe PG, Kennelly SP, Kern S, Klöppel S, Krajčovičová L, Kramberger MG, McGuinness B, Mecocci P, Oberstein TJ, Ousset PJ, Paquet C, Perneczky R, Piazza F, Plantone D, Rainero I, Sacco G, Salmon E, Santana I, Scarmeas N, Schneider A, Schott JM, Solje E, Stefanova E, Stögmann E, Strauss M, Sutovsky S, Waldemar G, Winblad B.
Jessen F, et al. Among authors: ivanoiu a.
J Prev Alzheimers Dis. 2025 Sep;12(8):100259. doi: 10.1016/j.tjpad.2025.100259. Epub 2025 Jul 9.
J Prev Alzheimers Dis. 2025.
PMID: 40640062
Free PMC article.
No abstract available.